Q4 2025 Artivion Inc Earnings Call Transcript

Feb 12, 2026 / 09:30 PM GMT

Release Date Price: $40.65 (+1.37%)

Transcript 10-K8-K

Key Points

Positve

Artivion Inc (AORT) reported a 13% year-over-year growth in total adjusted constant currency revenue for 2025.
Adjusted EBITDA grew by 26% year-over-year, indicating strong operational performance.
Stent graft revenues increased by 36% in Q4 2025, driven by strong growth in the US and international markets.
Onyx revenues grew by 24% year-over-year, supported by global market share gains and new clinical data.
Positive clinical trial data from AMDS Persevere and Nexus Triumph trials support future growth and regulatory approvals.

Negative

The cybersecurity incident in 2024 had lingering impacts, particularly affecting tissue processing revenues.
The Italian government's payback legislation resulted in a $2.3 million adjustment to revenue for fiscal years 2019 through 2025.
Tissue processing revenue growth was below expectations, declining 3% for the full year compared to 2024.
Gross margins were negatively impacted by the Italian payback adjustment and manufacturing inefficiencies.
Increased R&D expenses are expected in 2026, which may impact short-term profitability.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

AORT.N - Artivion Inc
Q4 2025 Artivion Inc Earnings Call
Feb 12, 2026 / 09:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good afternoon and welcome to the RTVN 4th quarter and year-end 2025 earnings call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press 0 on your telephone keypad. As a reminder, this conference is being recorded. I would now like to turn the conference over to Lane Morgan from the Gilmartin Group.

Thank you. You may begin.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thanks, operator. Good afternoon and thank you for joining

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.